Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy

[1] Wee JT(2010)Is nasopharyngeal cancer really a “Cantonese cancer”? Chin J Cancer 29 517-526

[2] Ha TC(2015)A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events Radiat Oncol 10 166-3690

[3] Loong SL(2009)Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225 J Clin Oncol 27 3684-1078

[4] Qian CN(2009)Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series Int J Radiat Oncol Biol Phys 75 1071-145

[5] Songthong AP(2010)Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma Int J Radiat Oncol Biol Phys 76 138-403

[6] Kannarunimit D(2014)Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities Radiother Oncol 110 398-24216

[7] Chakkabat C(2016)Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status Oncotarget 7 24208-982

[8] Lertbutsayanukul C(2017)Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma? J Cancer 8 976-1776

[9] Lee N(2017)Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: a meta-analysis PLoS One 12 e0181478-1466

[10] Harris J(2013)A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma PLoS One 8 e83069-E1340

[1] Wee JT(2010)Is nasopharyngeal cancer really a “Cantonese cancer”? Chin J Cancer 29 517-526

[2] Ha TC(2015)A randomized phase II/III study of adverse events between sequential (SEQ) versus simultaneous integrated boost (SIB) intensity modulated radiation therapy (IMRT) in nasopharyngeal carcinoma; preliminary result on acute adverse events Radiat Oncol 10 166-3690

[3] Loong SL(2009)Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225 J Clin Oncol 27 3684-1078

[4] Qian CN(2009)Nasopharyngeal carcinoma treated with reduced-volume intensity-modulated radiation therapy: report on the 3-year outcome of a prospective series Int J Radiat Oncol Biol Phys 75 1071-145

[5] Songthong AP(2010)Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma Int J Radiat Oncol Biol Phys 76 138-403

[6] Kannarunimit D(2014)Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities Radiother Oncol 110 398-24216

[7] Chakkabat C(2016)Survival analysis of patients with advanced-stage nasopharyngeal carcinoma according to the Epstein-Barr virus status Oncotarget 7 24208-982

[8] Lertbutsayanukul C(2017)Is pretreatment Epstein-Barr virus DNA still associated with 6-year survival outcomes in locoregionally advanced nasopharyngeal carcinoma? J Cancer 8 976-1776

[9] Lee N(2017)Prognostic role of neutrophil-lymphocyte ratio in nasopharyngeal carcinoma: a meta-analysis PLoS One 12 e0181478-1466

[10] Harris J(2013)A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma PLoS One 8 e83069-E1340